EyePoint, Inc. (EYPT) Stock
Healthcare · Biotechnology · Member of Other US Stocks
EyePoint, Inc. (EYPT) closed at USD 3.01 on 2026-10-14, a change of -75.4 % over the past year, with a market capitalization of USD 270.71M.
EyePoint, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 3.01 |
| 2026-10-13 | 3.07 |
| 2026-10-12 | 3.32 |
| 2026-10-09 | 3.40 |
| 2026-10-08 | 3.46 |
| 2026-10-07 | 3.32 |
| 2026-10-06 | 3.17 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
EyePoint, Inc. key figures
- Previous close
- USD 3.01 (2026-10-14)
- 1-year change
- -75.4 %
- Market cap
- USD 270.71M
- Enterprise value
- USD 112.6M
- P/E ratio (trailing)
- -0.81
- P/E ratio (forward)
- -1.13
- EPS (trailing)
- -3.87
- EPS (forward)
- -2.78
- PEG ratio
- n/a
- Price to book
- 1.60
- Revenue growth
- -90.5 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 5.85
- Employees
- 214
- Analyst consensus (third-party)
- buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for EyePoint, Inc. and compare it with other stocks.
Analyze EYPTAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell EyePoint, Inc. shares.